Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00000452 · ClinicalTrials.gov registry record · Phase 4

Naltrexone Treatment of Alcohol Dependence

A Phase 4 study, sponsored by National Institute on Alcohol Abuse and Alcoholism (NIAAA).

Completed
Registry status
Phase 4
Development phase
240
Enrollment target

NCT00000452: Completed Phase 4 study, sponsored by National Institute on Alcohol Abuse and Alcoholism (NIAAA).

NCT00000452 is a Phase 4 study that has completed, run by National Institute on Alcohol Abuse and Alcoholism (NIAAA). The registered enrollment target is 240 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (54% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00000452, a Phase 4 study, has completed, sponsored by National Institute on Alcohol Abuse and Alcoholism (NIAAA).

COMPLETED
Registry status
Phase 4
Development phase
240 participants
Enrollment target

Study Summary

The long-range goal of this ongoing research program is to find more effective treatments for alcohol dependence by combining medication with the appropriate psychosocial support. This proposal has three specific aims: (1) to compare the effectiveness of naltrexone (Revia) in three types of treatment settings; (2) to assess the effects of psychosocial support on medication compliance and treatment retention; and (3) to investigate the individual characteristics that may predict who is likely to benefit from additional psychosocial support versus simple medication management.

Interventions

  • BEHAVIORAL Cognitive Behavior Therapy
  • DRUG naltrexone (Revia)
  • BEHAVIORAL Compliance Enhancement Tech.

Trial Details

FieldValue
Enrollment Target 240 participants
Est. Completion 2003-01
Phase Phase 4

What the finished NCT00000452 record still lists

NCT00000452 is an interventional study that assigns participants to a tested intervention. The registered 240 participants enrollment target is mid-sized for trials with a published cap, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (54% lower).

The record links to 0 conditions, and to 3 interventions - of which Cognitive Behavior Therapy is the first listed.

NCT00000452 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT00000452 about?

NCT00000452 is a clinical study titled "Naltrexone Treatment of Alcohol Dependence". The long-range goal of this ongoing research program is to find more effective treatments for alcohol dependence by combining medication with the appropriate psychosocial support. This proposal has three specific aims: (1) to compare the effectiveness of naltrexone (Revia) in three types of treatmen...

What is the current status of trial NCT00000452?

This trial is currently completed. It is a Phase 4 study. The enrollment target is 240 participants. Estimated completion is 2003-01.

What interventions are being tested in trial NCT00000452?

The interventions under investigation include: Cognitive Behavior Therapy (BEHAVIORAL), naltrexone (Revia) (DRUG), Compliance Enhancement Tech. (BEHAVIORAL).

Who is sponsoring clinical trial NCT00000452?

This trial is sponsored by National Institute on Alcohol Abuse and Alcoholism (NIAAA), which has 93 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT00000452's enrollment target sits among peer trials

240 360th of 2000 higher than 1,635 of 2,000 other Phase 4 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02855554 · 240 participants · NA

    Quantitative Cardiac Parametric Mapping

  • NCT03230565 · 240 participants · Phase 4

    Continuous Infusions vs Scheduled Bolus Infusions

  • NCT03399929 · 240 participants

    Traumatic Brain Injury and Stroke Long Term Outcome

  • NCT03583710 · 240 participants · Phase 3

    Mitotane With or Without Cisplatin and Etoposide After Surgery in Treating Patients With Stage I-III Adrenocortical Cancer With High Risk of Recurrence

Source: ClinicalTrials.gov NCT00000452, the US trial registry maintained by the National Library of Medicine. NCT00000452 (mid enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.